Pfizer COVID-19 vaccine. Courtesy: Pfizer The U.S. Centers for Disease Control and Prevention on Wednesday recommended expanding the use of vaccines to adults between 50-64 years to protect against pneumococcal disease. The agency's earlier recommendation for vaccination was for adults 65 year...
Merck offers three approved pneumococcal vaccines, including Vaxneuvance for individuals aged six weeks and older and Pneumovax 23 for adults over 50 and children above two. In June, the U.S. health regulator approved Capvaxive, Merck's next-generation vaccine that helps ...
Conjugate Pneumococcal Vaccine and AdultsSynopsis: While Prevnar 13 has received FDA approval for use in adults aged 50 years and older, the CDC recommends continued use of the 23-valent polysaccharide pneumococcal v...
老年人肺炎链球菌疫苗的接种建议 CDC recommends 2 pneumococcal vaccines for adults 65 years or older. You should receive a dose of the pneumococcal conjugate vaccine (PCV13) first, followed at least one year later by a dose of ...
Adults who have gotten the PCV13 dose but not the previously recommended PPSV23 vaccines are eligible for a single dose of PCV20 or one or more doses of the PPSV23 vaccine. “CDC and ACIP will continue to assess the safety of PCV15 and PCV20 use in adults, monitor...
other pneumococcal vaccines are available in the US: Prevnar 13 (PCV13; Pfizer), a 13-valent conjugate vaccine licensed for use in persons ≥6 weeks old, and Pneumovax 23 (PPSV23; Merck), a 23-valent pneumococcal polysaccharide vaccine licensed for use in persons ≥2 years old (Tabl...
The recommended first age at which Americans should get the pneumococcal vaccine has been lowered from 65 to 50, the U.S. Centers for Disease Control and Prevention announced Wednesday.
an epidemiologist and CDC liaison to the pneumococcal vaccine work group for the Advisory Committee on Immunization Practices (ACIP). Thank you for tuning in to thisCDC Expert Video Commentaryon Medscape. I would like to talk to you about pneumococcal disease among adults and opportunities we have...
In: DiPiro JT, Talbert RL, Yee GC, et al., eds. Pharmacotherapy: A Pathophysiologic Approach. 5th ed. New York, NY: McGraw-Hill; 2002:1849-1867. 2. Pneumococcal polysaccharide vaccine: what you need to know. Centers for Disease Control and Prevention. Available at: www.cdc.gov/nip/...
A 20-valent pneumococcal conjugate vaccine (PCV20) had a similar safety and tolerability profile to 13-valent PCV (PCV13) and elicited robust immune responses to 20 vaccine serotypes 1 month after vaccination in adults 18 years or older in a phase 3trial, researchers recently reported inClinic...